Check Case Studies on Inclusion Across the Lifespan
As you plan your human subjects research, use the Inclusion Across the Lifespan Case Studies to help you determine if your proposed study population is appropriate. Following the Inclusion Across the Lifespan policy, NIH-supported research must include individuals of all ages unless there is a scientific or ethical reason not to include a specific age group.
The Case Studies summarize the scientific and ethical aspects of age-related inclusion in four fictional study scenarios. Consider Case #1:
Study summary: An investigator is planning a study analyzing stress and anxiety levels in children involved in care...
Source: NIH Extramural Nexus - December 4, 2023 Category: Research Authors: NIH Staff Tags: New Resources human subjects Inclusion inclusion across the lifespan Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity PAR-23-102 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 13, 2023 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity PAR-23-097 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and p...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 6, 2023 Category: Research Source Type: funding
Racial Equity in Postpartum Care Challenge: Innovative Methods to Improve Postpartum Care for Black or African American and American Indian/Alaska Native Women
A prize competition to identify effective programs that can address equity of postpartum care for Black or African American and American Indian/Alaska Native beneficiaries enrolled in Medicaid or CHIP. An emphasis is on follow-up care for conditions associated with morbidity and mortality in the later postpartum period, including diabetes, postpartum depression, postpartum anxiety, hypertension, and substance use disorders. Geographic coverage: Nationwide -- Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services, U.S. Department of Health and Human Services Office on Women's Health (Source...
Source: Funding opportunities via the Rural Health Information Hub - November 16, 2021 Category: American Health Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity PAR-22-035 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-105 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 20, 2021 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity PAR-22-036 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 20, 2021 Category: Research Source Type: funding
NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-244 from the NIH Guide for Grants and Contracts. The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3....
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 10, 2021 Category: Research Source Type: funding
Parenting in a Time of COVID
Guest post by Carrie Wolinetz, Ph.D., NIH Associate Director for Science Policy, originally released on the Under the Poliscope blog
Carrie Wolinetz, Ph.D.,Associate Director for Science Policy, NIH
Next week marks the one-year anniversary of NIH shifting to maximum telework in response to the COVID-19 pandemic. Like employers and employees across the country, overnight we needed to adapt our entire enterprise and reinvent our jobs in the virtual workplace. Coincidentally, next week is also when with a deep breath and a big hug, I send my six year old back to school in person, masked up and excited to meet his 1st grade...
Source: NIH Extramural Nexus - March 9, 2021 Category: Research Authors: Carrie Wolinetz Tags: blog Open Mike COVID COVID-19 Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity RFA-MH-21-106 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2020 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity RFA-MH-21-105 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2020 Category: Research Source Type: funding
Characterizing causal mechanisms to prevent dental fear and anxiety (R01 Basic Experimental Studies with Humans Required)
Funding Opportunity RFA-DE-21-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to test causal mechanisms underlying the etiology or prevention of dental fear, anxiety, or phobia. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 26, 2020 Category: Research Source Type: funding
Secondary Data Analysis to Examine Long-Term and/or Potential Cross-Over Effects of Prevention Interventions: What are the Benefits for Preventing Mental Health Disorders? (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-20-110 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage research to integrate/harmonize existing data sets from preventive intervention trials implemented early in life to: 1) examine risk and protective factors relevant to later mental health outcomes in childhood, adolescence and young adulthood; and 2) determine whether preventive interventions delivered earlier in life have long-term effects, and/or cross-over effects (e.g., unanticipated beneficial effects), on important mental health outcomes, including serious mental...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 6, 2019 Category: Research Source Type: funding
HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers (U01 Clinical Trial Required)
Funding Opportunity RFA-DK-18-030 from the NIH Guide for Grants and Contracts. Pain is a common problem in Medicare End-Stage Renal Disease (ESRD) Hemodialysis (HD) patients, but its prevalence varies widely by geography, dialysis unit, and possibly, ethnicity. Pain has been linked to decreased quality of life, lack of social support, depressed mood and other mental health disorders. Chronic opioid prescription has been identified in approximately 20% of US ESRD HD patients, far higher than in Medicare comparison populations. Opioid doses prescribed to HD patients exceed Centers for Disease Control and Prevention (CDC) ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 10, 2018 Category: Research Source Type: funding
HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Scientific and Data Research Center (U01 Clinical Trial Required)
Funding Opportunity RFA-DK-18-031 from the NIH Guide for Grants and Contracts. Pain is a common problem in Medicare End-Stage Renal Disease (ESRD) Hemodialysis (HD) patients, but its prevalence varies widely by geography, dialysis unit, and possibly, ethnicity. Perception of pain has been linked to decreased quality of life, lack of social support, depressed mood and other mental health disorders. Chronic opioid prescription has been identified in approximately 20% of US ESRD HD patients, far higher than the rate in Medicare comparison populations. Opioid doses prescribed to HD patients exceed Centers for Disease Contro...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 10, 2018 Category: Research Source Type: funding
HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers (U01 Clinical Trial Required)
Pain is a common problem in Medicare End-Stage Renal Disease (ESRD) Hemodialysis (HD) patients, but its prevalence varies widely by geography, dialysis unit, and possibly, ethnicity. Pain has been linked to decreased quality of life, lack of social support, depressed mood and other mental health disorders. Chronic opioid prescription has been identified in approximately 20% of US ESRD HD patients, far higher than in Medicare comparison populations. Opioid doses prescribed to HD patients exceed Centers for Disease Control and Prevention (CDC) recommendations. Prescription and dose level have been associated with increased h...
Source: NIDDK Funding Opportunities - December 10, 2018 Category: Endocrinology Source Type: funding
